Toward understanding the molecular architecture of a glycogen-committed PP1/PTG holoenzyme: a putative target for lafora disease

Read full text Summarise with VIRAT
Authors: Paola Storici, Marta Stefania Semrau, Rachele Ortolan, G. Giachin, Andrea Dalle Vedove, Sonia Covaceuszach, Alberto Cassetta, Graziano Lolli
Cited by: 0
References: 2

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Lafora disease (LD), a fatal incurable neurodegenerative disorder characterized by teenage-onset progressive epilepsy, due to mutations in the EPM2A and EPM2B genes encoding laforin and malin, respectively.The pathophysiological status is correlated to the accumulation of insoluble polyglucosans in brain, determined by an increased glycogen production.In healthy brain cells, the malin/laforin E3-ligase complex regulates, among others, the degradation of PTG (Protein Targeting to Glycogen), a scaffolding protein involved in the activation of glycogen synthesis.PTG carries the type 1 protein phosphatase (PP1) to its substrates: glycogen synthase (GYS) and glycogen phosphorylase (PYG).At the molecular level, loss-of-function mutations in laforin or malin cause PTG accumulation, leading to abnormal glycogen aggregation and formation of neurotoxic Lafora bodies (LB) that drive neurodegeneration.

Fields of Study & Subjects

Glycogen Storage Diseases and Myoclonus Biomedical Research and Pathophysiology Metabolism Diabetes and Cancer

Publication details

Journal / source
Acta Crystallographica Section A Foundations and Advances
Volume
81
Issue
a1
Pages
e10–e10
Publication date
30 March 2026
Language
EN